

## From Europe

### Recently Activated EORTC Protocols

Eleven new EORTC (or intergroup) protocols were activated in July–December 1996. These are listed in the panel. Any physician willing to take part in one of these protocols may contact the study coordinator or the study's Coordinating Centre as appropriate (EORTC Data Centre, Fax: 32 2 772 35 45. EORTC NDDO, Fax: 31 20 444 27 67.)

Participation in EORTC or intergroup trials can only be considered once the appropriate application for memberships has been received by the relevant cooperative group, if the physician is not already a member.

#### **Coordinating centre: EORTC Data Centre, Brussels, Belgium**

**22954 Phase III study on larynx preservation comparing radiotherapy versus concomitant radio-chemotherapy in resectable hypopharynx and larynx cancers:** an EORTC Radiotherapy/Head and Neck Cooperative Groups protocol  
Target accrual: 564 patients  
Trial coordinators: Professor Jean-Claude Horiot (France), Fax: 33 380362829; Dr Jean-Louis Lefebvre (France), Fax: 33 320295961

**24954 Phase III study on larynx preservation comparing induction chemotherapy and radiotherapy versus alternating chemo-radiotherapy in resectable hypopharynx and larynx cancers:** an EORTC Head and Neck/Radiotherapy Cooperative Groups protocol  
Target accrual: 564 patients  
Trial coordinators: Professor Jean-Claude Horiot (France), Fax: 33 380362829; Dr Jean-Louis Lefebvre (France), Fax: 33 320295961

**22922 Phase III randomised clinical trial investigating the role of internal mammary and medial supraclavicular (IM-MS) lymph node chain irradiation in stage I–III breast cancer:** an EORTC Radiotherapy/Breast Cancer Cooperative Groups protocol  
Target accrual: 4000 patients  
Trial coordinators: Professor Walter Van Den Boghaert (Belgium), Fax: 32 16 346901; Dr P. Romestaing (France), Fax: 33 4 78 50 6515; Dr H. Struikmans (The Netherlands), Fax: 31 30 2513399

**08957 Phase II study on topotecan in combination with cisplatin as second line treatment of small cell lung cancer:** an EORTC Lung Cancer Cooperative Group protocol  
Target accrual: 108 patients  
Trial coordinators: Dr Andrea

Ardizzoni (Italy), Fax: 39 10 355562; Dr Christan Manegold (Germany), Fax: 49 6221 396541

**40961 A phase II trial: weekly high-dose 5-FU and folinic acid in metastatic pancreatic carcinoma:** an EORTC Gastrointestinal Tract Cancer Cooperative Group protocol  
Target accrual: 1st stage= 18 patients  
2nd stage= 14 patients  
Trial coordinator: Dr Ruud E.N. Van Rijswijk (The Netherlands), Fax: 31 43 3875006

**10961 Doxorubicin/ Taxol combination as first-line chemotherapy in metastatic breast cancer: a randomised study versus standard doxorubicin/cyclophosphamide combination regimen:** an EORTC Breast Cancer Cooperative/Early Clinical Studies Groups protocol  
Target accrual: 260 patients  
Trial coordinators: Dr Martine Piccart (Belgium), Fax: 32 2 5380858; Dr Per Dombornowsky (Denmark), Fax: 45 44535332

**26951 Phase III study of adjuvant Procarbazine, CCNU and vincristine chemotherapy in patients with highly anaplastic oligodendroglioma:** an EORTC Brain Tumours Cooperative Group protocol  
Target accrual: 292 patients  
Trial coordinator: Dr M.J. Van Den Bent (The Netherlands), Fax: 31 10 4845743

**22952 Convergent beam irradiation of cerebral metastases: an EORTC Radiotherapy Cooperative Group phase III protocol**  
Target accrual: 340 patients  
Trial coordinator: Professor Rolf Peter Muller (Germany), Fax: 49 221 4786158

**06961 Autologous peripheral blood stem cell transplantation (PSCT) versus a second intensive consolidation course in patients**

**with bad prognosis myelodysplastic syndromes (MDS) and acute myelogenous leukaemia secondary (SAML) to MDS of more than 6 months duration:** an EORTC Leukaemia Cooperative Group/EBMT Chronic Leukaemia Working Party/GIMEMA/SAKK/HOVON protocol  
Target accrual: 250 patients  
Trial coordinators: Professor Theo de Witte (The Netherlands), Fax: 31 24 3542080; Dr G.E.G. Verhoef (Belgium), Fax: 32 16 344604; Professor Franco Mandelli (Italy), Fax: 39 6 857995293; Professor H.E. Hess (Switzerland), Fax: 41 71 256805

**22962 A phase III study comparing conventional versus hyper-fractionated radiotherapy, with or without concomitant chemotherapy, in patients with head and neck squamous cell carcinoma:** an EORTC Radiotherapy Cooperative Group protocol  
Target accrual: 994 patients  
Trial coordinators: Professor Jean-Claude Horiot (France), Fax: 33 380362829; Dr Jacques Bernier (Switzerland) Fax: 41 91 8255952

#### **Coordinating centre: EORTC New Drug Development Office, Amsterdam, The Netherlands**

**13961 A phase II trial in patients with early cervical cancer to study the safety and the immunological effects of vaccination with TA-HPV, a live recombinant vaccinia virus expressing the human papilloma virus 16 and 18 E6 and E7 proteins:** an EORTC Biological Therapeutics Development Group protocol  
Target accrual: 1st stage=28 patients  
2nd stage= 16 patients  
Trial coordinator: Dr Jantien Wanders (The Netherlands), Fax: 31 20 444 2767